Progress in the application of neoadjuvant therapy in radical prostatectomy

Hong Baoan,Zhao Qiang,Yang Yong,Du Peng

DOI: https://doi.org/10.20020/j.CNKI.1674-7410.2022.04.02

2022-01-01

Abstract:Prostate cancer is one of the most common malignant tumors in the urogenital system.Its incidence and mortality were increasing year by year in our country.Moreover,the proportion of locally advanced and metastatic patients were about 70% of the newly diagnosed patients.Clinically,radical prostatectomy alone is not effective for high-risk or locally advanced prostate cancer,which is related to adverse pathological factors such as positive surgical margin,prostate capsule invasion,and seminal vesicle invasion,resulting in a high postoperative biochemical recurrence.Therefore,in addition to radical prostatectomy,it is necessary to explore multi-mode combined treatment strategies to improve long-term efficacy and prognosis,among which neoadjuvant therapy is an important exploration direction.The neoadjuvant therapy regimens include hormonal therapy（androgen-deprivation therapy,ADT）,chemotherapy,hormonal therapy combined with chemotherapy,etc.Some studies have shown that neoadjuvant therapy can reduce tumor volume,improve surgical resection rate,reduce tumor staging,and reduce the positive rate of surgical margin.However,there are still controversies in terms of prolonging disease-specific survival and overall survival,and there is currently a lack of large sample prospective randomized controlled studies.Neoadjuvant therapy depends on effective hormonal agents.In recent years,with the gradual expansion of indications of new endocrine drugs in metastatic prostate cancer,the exploration of neoadjuvant therapy for prostate cancer is also increasing,and whether it can achieve long-term survival benefits needs further research.In this paper,progress in the application of neoadjuvant therapy in radical prostatectomy will be briefly summarized.